Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420783 | 1.00 | EPHX2 (0.41) | EPHX2FLT3DHODHMAPK14RET | |
| SCHEMBL29420794 | 0.89 | EPHX2 (0.44) | EPHX2FLT3RET | |
| SCHEMBL24754845 | 0.89 | EPHX2 (0.44) | EPHX2FLT3RET | |
| SCHEMBL29420788 | 0.87 | EPHX2 (0.43) | EPHX2FLT3 | |
| SCHEMBL22931804 | 0.87 | EPHX2 (0.43) | EPHX2FLT3MAPK14RET | |
| SCHEMBL24754812 | 0.87 | EPHX2 (0.43) | EPHX2FLT3 | |
| SCHEMBL29420791 | 0.87 | EPHX2 (0.43) | EPHX2FLT3MAPK14RET | |
| SCHEMBL24755078 | 0.82 | EPHX2 (0.42) | EPHX2DHODH | |
| SCHEMBL29420789 | 0.82 | EPHX2 (0.42) | EPHX2DHODH | |
| SCHEMBL22931769 | 0.80 | EPHX2 (0.52) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARM INT AG (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2021018869-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | OXER1, CBR3, CCNY | EPHX2 755/4885FLT3 707/4885DHODH 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.